Skip to main content

Birch Pollen Allergy

6
Pipeline Programs
2
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
3 programs
1
2
Recombinant birch pollenPhase 31 trial
recombinant birch pollen allergen (rBet v1-FV)Phase 3
Recombinant birch pollenPhase 21 trial
Active Trials
NCT00266526CompletedEst. Jul 2005
NCT00309062CompletedEst. Jun 2009
Desentum
DesentumFinland - Espoo
3 programs
2
1
DM-101PXPhase 21 trial
DM-101Phase 12 trials
DM-101PXPhase 11 trial
Active Trials
NCT07898800Not Yet Recruiting40Est. May 2027
NCT04266028Completed27Est. May 2021
NCT06037148Completed30Est. Mar 2024
+1 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
AllergopharmaRecombinant birch pollen
DesentumDM-101PX
AllergopharmaRecombinant birch pollen
DesentumDM-101
DesentumDM-101PX
DesentumDM-101

Clinical Trials (6)

Total enrollment: 194 patients across 6 trials

NCT00309062AllergopharmaRecombinant birch pollen

Safety and Efficacy of Recombinant Birch Pollen Allergen in the Treatment of Allergic Rhinoconjunctivitis

Start: Dec 2003Est. completion: Jun 2009
Phase 3Completed
NCT07254871DesentumDM-101PX

Study of DM-101PX in Adults With Birch Pollen Allergy

Start: Sep 2025Est. completion: Aug 202697 patients
Phase 2Completed
NCT00266526AllergopharmaRecombinant birch pollen

Specific Immunotherapy With Recombinant Birch Pollen Allergen rBet v1-FV

Start: Jul 2003Est. completion: Jul 2005
Phase 2Completed
NCT07898800DesentumDM-101

Safety, Tolerability And Pharmacodynamics of DM-101PX in Birch Pollen Allergy

Start: Nov 2026Est. completion: May 202740 patients
Phase 1Not Yet Recruiting
NCT06037148DesentumDM-101PX

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

Start: Sep 2023Est. completion: Mar 202430 patients
Phase 1Completed
NCT04266028DesentumDM-101

Study to Evaluate Safety and Tolerability of sc Immunotherapy With DM-101 in Adults With Birch Pollen Allergy

Start: Feb 2020Est. completion: May 202127 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.